The expert panel had convened a meeting to take a call on the emergency use authorisation sought by the Serum Institute of India, the manufacturer of Covishield, and Bharat Biotech for its Covaxin.
Once the vaccines are cleared by the committee, the application will be sent to Drugs Controller General of India (DCGI) V.G. Somani for final approval.
The decision paved the way for the vaccine’s rollout in India, which also has the highest number of infections in the world, after the US.
The UK and Argentina have already approved the vaccine. More than five crore doses of the vaccine have already been stockpiled by its manufacturer, the Pune-based Serum Institute of India.